What Clinical Evidence Shows for 1.7mg Wegovy
Wegovy 1.7mg Weight Loss Results: Clinical Trial Evidence
In clinical trials, patients taking Wegovy alongside diet and exercise achieved significant weight management outcomes. The landmark STEP 1 trial, published by Wilding et al. in the New England Journal of Medicine (2021), demonstrated approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo. The 1.7mg dose represents weeks 13-16 of this evidence-based escalation protocol, positioning patients for optimal therapeutic benefit as they approach maintenance therapy.
The STEP 5 trial extended follow-up to two years, showing sustained weight loss of approximately 15.2% with continued Wegovy treatment. This prescription-only medicine works as a GLP-1 receptor agonist, mimicking natural fullness hormones to reduce appetite and promote satiety after smaller meals. At 1.7mg, patients typically experience the therapeutic effects building towards the full 2.4mg maintenance dose.
1.7mg Wegovy Pricing and Bundle Options UK
EverydayMeds offers Wegovy 1.7mg pens for £139.99, with convenient bundle options for seamless dose progression. The Elevate Duo (1.7mg + 2.4mg) costs £369.99, providing your transition to maintenance therapy in one order. This eliminates multiple deliveries and ensures continuous supply during your critical dose escalation phase. Returning customers can apply code DOSE25 at checkout for optimal pricing.
The Consistency 1.7mg bundle provides two identical pens for £309.99, ideal if your prescriber recommends extending this dose phase. Our Elevate Trio (1mg, 1.7mg, 2.4mg) costs £499.99 for a complete step-up progression. All prices include cold-chain delivery and clinical assessment processing through our GPhC-registered facility. New customers use code FIRST40 at checkout to achieve these competitive rates.
STEP Trial Results for 1.7 Wegovy Dose Progression
The 1.7mg dose sits strategically within the STEP trial protocols as the penultimate escalation step. Clinical evidence shows this dose helps prepare patients for maintenance therapy, with the GLP-1 receptor agonist mechanism reaching near-optimal therapeutic activity. In STEP 3, patients receiving intensive behavioural therapy alongside Wegovy achieved approximately clinically studied weight loss, highlighting the importance of lifestyle modifications during dose escalation.
The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events with Wegovy treatment. This prescription-only medicine may help reduce appetite and food cravings by acting on brain appetite centres, with effects typically building throughout the 1.7mg phase before reaching full therapeutic potential at 2.4mg maintenance.
How 1.7mg Wegovy Works in Your System
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormones responsible for blood sugar regulation and appetite control. At the 1.7mg dose, administered once weekly via FlexTouch pen injection, the medication works by slowing gastric emptying and enhancing insulin sensitivity when blood glucose levels rise. The 1.7mg strength represents 71% of the full maintenance dose, allowing your system to adapt whilst building therapeutic benefit. This dose typically helps patients feel satisfied with smaller portions and may reduce between-meal cravings. The once-weekly injection schedule maintains consistent medication levels, with peak effectiveness building as you approach the final 2.4mg dose escalation in weeks 17 onwards.
EverydayMeds 1.7mg Wegovy Ordering Process
Obtaining your 1.7mg Wegovy prescription through EverydayMeds begins with our 3-minute online clinical assessment, designed specifically for patients progressing through dose escalation. Our UK-qualified prescribers review your application within 3 working days (or 24 hours with express service), considering your previous Wegovy experience and current treatment phase. Once approved, your 1.7mg pen ships via temperature-controlled next-day delivery, maintaining the 2-8°C cold-chain requirement until it reaches your door. Our GPhC-registered pharmacy (#9012878) ensures all medications meet MHRA standards with full traceability. You'll receive injection guidance and dose escalation planning to support your transition to 2.4mg maintenance therapy.
Storing Your 1.7mg Wegovy Pen Correctly
Proper storage ensures your 1.7mg Wegovy maintains full potency throughout the 4-week usage period. Keep unused pens refrigerated at 2-8°C until first use, after which the FlexTouch pen can remain at room temperature below 30°C for up to 6 weeks - longer than competing treatments like Mounjaro's 21-day limit. Each pen contains 4 doses of 1.7mg semaglutide, sufficient for the complete weeks 13-16 dose escalation phase. Never freeze the medication, and protect from direct sunlight during storage. The FlexTouch pen mechanism delivers precise 1.7mg doses with an audible click confirmation. Cap the pen after each injection and dispose of used needles safely in a sharps container provided with your order.
Why 1.7mg Represents Peak Wegovy Escalation in UK Treatment
The 1.7mg Wegovy dose occupies a unique position in UK weight management protocols, representing the final escalation step before maintenance therapy. Unlike lower doses focused on tolerance building, 1.7mg delivers substantial therapeutic benefit whilst preparing patients for long-term 2.4mg treatment. This dose phase coincides with the 12-16 week period where clinical trials show accelerating weight management results. UK prescribers often use this phase to assess patient response and optimise lifestyle interventions before maintenance.
At 1.7mg, patients typically experience the full appetite suppression mechanism without the initial adjustment period of earlier doses. This creates an optimal window for establishing sustainable eating patterns and exercise routines that support long-term success. The dose bridges the gap between the 1mg therapeutic threshold and 2.4mg maintenance, ensuring smooth progression without efficacy gaps or tolerance issues that might compromise treatment outcomes.
Secure Your 1.7mg Wegovy Supply Today
EverydayMeds maintains consistent 1.7mg Wegovy availability through our direct Novo Nordisk supply chain, ensuring your dose escalation never faces interruption. Access your prescription-only medicine through our streamlined process, with clinical assessment, prescriber approval, and next-day delivery typically completed within 72 hours. New customers apply FIRST40 at checkout, whilst returning patients use DOSE25 for continued savings on their 1.7mg supply. Our clinical team supports your progression to 2.4mg maintenance, with bundle options available for seamless transition. Visit https://everydaymeds.co.uk/products/wegovy-1-7mg to begin your clinical assessment and continue your evidence-based weight management journey with confidence.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
